299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03045198
(ClinicalTrials.gov)
March 20122/2/2017Effect of Azithromycin on Fatty Acids in CFEffect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic FibrosisCystic FibrosisDrug: AzithromycinUniversity Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)University of Bonn;University Hospital, FrankfurtUnknown status10 Years60 YearsAll20Phase 4NULL
2NCT01783613
(ClinicalTrials.gov)
October 201131/1/2013Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic FibrosisStudy of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic FibrosisCystic FibrosisDietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months;Dietary Supplement: Placebo: 50 mg/kg/day during 12 monthsFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNULLCompleted2 Months100 YearsAll96N/ASpain
3EUCTR2010-020516-11-IT
(EUCTR)
16/09/201028/09/2010EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - NDEXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY
MedDRA version: 9.1;Level: PT;Classification code 10033628
MedDRA version: 9.1;Classification code 10011762
Trade Name: PREFOLIC*30CPR GASTROR 15MG
INN or Proposed INN: Detoxifying agents for antineoplastic treatment
Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML
INN or Proposed INN: Cobamamide
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
4NCT02690857
(ClinicalTrials.gov)
May 201016/2/2016Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)Efficacy of Docosahexanoic Acid on Lipid Peroxidation in Subjects With Cystic FibrosisCystic FibrosisDrug: Docosahexaenoic acid;Drug: Sunflower OilHospices Civils de LyonNULLCompleted6 Years30 YearsMale10Phase 2NULL
5NCT00530244
(ClinicalTrials.gov)
March 200313/9/2007Use of Formula Fortified With DHA in Infants With Cystic FibrosisThe Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)Cystic FibrosisDietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)University of Massachusetts, WorcesterCystic Fibrosis FoundationCompletedN/A56 DaysAll76N/AUnited States